INSY - INSYS Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.96
-0.13 (-1.83%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close7.09
Open7.05
Bid4.50 x 100
Ask7.28 x 100
Day's Range6.90 - 7.28
52 Week Range4.10 - 15.02
Volume588,306
Avg. Volume753,524
Market Cap513.4M
Beta2.24
PE Ratio (TTM)N/A
EPS (TTM)-3.16
Earnings DateMay 7, 2018 - May 11, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    INSYS Therapeutics to Advance Clinical Research of Dronabinol Inhalation Using Novel Breath-Actuated Device

    PHOENIX, April 18, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced plans to advance ...

  • Can Cannabis Treat Seizures? Biotechs Say The Answer Is Yes
    Investor's Business Daily3 days ago

    Can Cannabis Treat Seizures? Biotechs Say The Answer Is Yes

    GW Pharmaceuticals, Insys Therapeutics and Zynerba Pharmaceuticals are using cannabis-based therapies to treat a myriad of disorders, including seizures.

  • Bloomberg3 days ago

    Drug Made From Cannabis Plant Gets Backing From FDA Staff

    An experimental medication that could become the first drug derived from a marijuana plant approved in the U.S. received a boost from Food and Drug Administration staff.

  • Better Marijuana Stock: 22nd Century Group vs. Insys Pharmaceuticals
    Motley Fool6 days ago

    Better Marijuana Stock: 22nd Century Group vs. Insys Pharmaceuticals

    These two biotechs are big losers so far this year. But which has the better shot at being a winner over the long run?

  • Here's Why Insys Therapeutics Inc. Tanked 17% in March
    Motley Fool15 days ago

    Here's Why Insys Therapeutics Inc. Tanked 17% in March

    A handful of threats lobbed at opioid-based drugmakers pressured shares of the pain relief specialist following a dismal earnings report.

  • Investopedia17 days ago

    Top 4 Marijuana Stocks to Watch

    These four marijuana stocks are top picks that capitalize on the industry.

  • GlobeNewswire18 days ago

    INSYS Therapeutics Appoints Trudy Vanhove to Board of Directors

    PHOENIX, April 02, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the appointment of ...

  • 3 Most Heavily Shorted Marijuana Stocks -- Are the Naysayers Wrong?
    Motley Fool19 days ago

    3 Most Heavily Shorted Marijuana Stocks -- Are the Naysayers Wrong?

    Big bets have been placed against these marijuana stocks. But could they prove to be short-sighted?

  • GlobeNewswirelast month

    INSYS Therapeutics Reiterates Commitment to Compliant and Ethical Business Practices and Advancing Innovative Product Pipeline

    PHOENIX, March 19, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today released the following statement:. ...

  • Associated Presslast month

    5 doctors charged with taking kickbacks to tout painkiller

    Five New York City doctors were arrested Friday on charges that they accepted bribes and kickbacks from an Arizona-based pharmaceutical company to prescribe large volumes of a highly addictive painkiller. ...

  • Reuterslast month

    Five New York doctors charged with taking kickbacks from Insys

    Federal prosecutors on Friday brought charges against five New York doctors accused of taking kickbacks from Insys Therapeutics Inc in exchange for prescribing the company's potent fentanyl-based cancer pain medication. An indictment filed in Manhattan federal court said Gordon Freedman, Jeffrey Goldstein, Todd Schlifstein, Dialecti Voudouris and Alexandru Burducea received fees from Insys to participate as speakers in sham educational events.

  • Reuterslast month

    Five New York doctors charged with taking kickbacks from Insys

    Federal prosecutors on Friday brought charges against five New York doctors accused of taking kickbacks from Insys Therapeutics Inc in exchange for prescribing the company's potent fentanyl-based cancer pain medication. An indictment filed in Manhattan federal court said Gordon Freedman, Jeffrey Goldstein, Todd Schlifstein, Dialecti Voudouris and Alexandru Burducea received fees from Insys to participate as speakers in sham educational events.

  • Is Beaten-Down Marijuana Stock Insys Therapeutics a Bad-News Buy?
    Motley Foollast month

    Is Beaten-Down Marijuana Stock Insys Therapeutics a Bad-News Buy?

    The biotech's continued bad news could make its current share price look like a bargain.

  • Investopedialast month

    Top 4 Marijuana Stocks to Watch

    These four marijuana stocks are top picks that capitalize on the industry.

  • Ivy League Doctor Gets 4 Years in Prison for Insys Opioid Kickbacks
    Fortunelast month

    Ivy League Doctor Gets 4 Years in Prison for Insys Opioid Kickbacks

    Jerrold Rosenberg lost his medical license.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of INSY earnings conference call or presentation 8-Mar-18 10:00pm GMT

    Q4 2017 INSYS Therapeutics Inc Earnings Call

  • Reuterslast month

    Doctor in Insys opioid kickback scheme gets four years in prison

    A Rhode Island doctor was sentenced on Friday to more than four years in prison after admitting he took kickbacks from Insys Therapeutics Inc to prescribe its fentanyl-based cancer pain drug to people who did not suffer from the condition. Jerrold Rosenberg, 63, was sentenced by U.S. District Judge John McConnell in Providence, Rhode Island, who said the doctor effectively sold his medical license to a pharmaceutical company seeking to boost its profits. McConnell said patients were put at risk by Rosenberg, who has admitted the $188,000 Insys paid him in the form of speaker fees were a factor in his decision to write prescriptions for the medication, Subsys.

  • Ivy League Doctor Gets 4 Years in Prison for Insys Opioid Kickbacks
    Bloomberglast month

    Ivy League Doctor Gets 4 Years in Prison for Insys Opioid Kickbacks

    A Rhode Island doctor who took kickbacks from Insys Therapeutics Inc. officials for prescribing the company’s highly addictive liquid version of the opioid painkiller Fentanyl was sentenced to more than ...

  • Benzingalast month

    Piper Jaffray Loses Confidence In Insys Therapeutics, Downgrades Stock

    Insys Therapeutics Inc (NASDAQ: INSY ), a pharmaceutical company that focuses on a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients called Subsys , reported its ...

  • Investopedialast month

    Top 4 Marijuana Stocks to Watch

    These four marijuana stocks are top picks that capitalize on the industry.

  • Reuterslast month

    Rhode Island doctor in Insys opioid kickback probe faces sentencing

    A Rhode Island doctor is to be sentenced on Friday after admitting that he took kickbacks from Insys Therapeutics Inc in exchange for prescribing a fentanyl-based cancer pain drug produced by the company. Prosecutors have asked a federal judge in Providence, Rhode Island, to sentence Jerrold Rosenberg to 70 months in prison, saying he allowed his medical judgment to be corrupted by $188,000 in kickbacks paid by Insys disguised as speaker fees. Prosecutors said patients with chronic pain placed their trust in Rosenberg, only to be prescribed Insys' powerful opioid-based spray Subsys, which was approved by the U.S. Food and Drug Administration for use by people with cancer.

  • Associated Presslast month

    Insys Therapeutics reports 4Q loss

    On a per-share basis, the Chandler, Arizona-based company said it had a loss of 65 cents. Losses, adjusted for pretax expenses and stock option expense, were 20 cents per share. The specialty pharmaceutical ...

  • Reuterslast month

    Drugmaker Insys loss widens on lower Subsys sales

    Insys Therapeutics Inc on Thursday posted a bigger fourth-quarter loss than a year ago, hurt by higher costs and soft demand for Subsys, an opioid cancer pain medication at the center of a U.S. investigation. Revenue fell 42.6 percent over that period to $31.5 million, a decline Insys Chief Executive Saeed Motahari attributed to a drop in prescriptions of medications like Subsys containing fentanyl, a synthetic opioid, used to treat pain in cancer patients. "People are still reluctant to use this product even for appropriate patients that FDA has approved it," Motahari said on a conference call with analysts.

  • CNBClast month

    After-hours buzz: MAT, HAS, UNFI & more

    See which stocks are posting big moves after the bell.

  • GlobeNewswirelast month

    INSYS Therapeutics Reports Fourth Quarter and Full Year 2017 Results

    PHOENIX, March 08, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today reported financial results ...